Summary AOD-9604 is a compact, well-studied growth hormone fragment with a narrow lipolytic mechanism, a strong safety record in toxicology studies, and a clear position in metabolic research as a GH-receptor-independent tool compound
We help them safely stop medication without weight regain
The FDA is reportedly looking into these compounding companies for their advertising methods, but for now theyre still selling medications
Some horses seem to do remarkably well on very little
The STEP clinical trials demonstrated an average 14.9% reduction in body weight over 68 weeks, with one-third of participants losing over 20% of initial body weight
It's particularly compelling for patients who haven't achieved adequate response with semaglutide or tirzepatide, those with obesity and concurrent knee osteoarthritis, patients with metabolic liver disease, and anyone with a significant cardiovascular risk factor burden